Clover touts positive preclinical results for COVID-19 vaccine

By The Science Advisory Board staff writers

September 25, 2020 -- Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GlaxoSmithKline (GSK) or Dynavax.

The pairing induces a strong immune response and protection against SARS-CoV-2 in animal models, according to the firm. Rhesus macaques that received the vaccine were protected against SARS-CoV-2 infection, as demonstrated by clinical observations (protection from weight loss and increases in body temperature) and significant reduction in viral loads in lung tissues and swabs, with no signs of disease enhancement, the firm said. Also, the vaccine produced a Th1-polarized T-cell response in mice, rats, and monkeys.

The positive preclinical data supports Clover's decision to progress adjuvanted vaccine candidates using both adjuvants into the firm's ongoing phase I clinical study of S-Trimer, which started in June. The study has completed its enrollment of 150 adult and elderly participants. Based on preliminary results, Clover is enrolling an additional 200 participants in a phase I dose-expansion study. The firm also intends to initiate a global phase II/III vaccine efficacy study before the end of the year.

Clover's clinical trials are supported by funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI).

CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture...
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership,...

Copyright © 2020 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter